A new analysis of the one-year PARTNER 3 results show TAVR with Edwards Lifesciences Corp.’s Sapien 3 offers a modest disease-specific health status advantage over surgical valve replacement.
The one-year results from PARTNER 3, published in May, showed TAVR with Sapien 3 resulted in lower rates of death and rehospitalization at one year compared with surgery in patients with severe aortic stenosis at low surgical risk. The PARTNER 3 results led the US Food and Drug Administration to expand the approved labeling for Sapien 3 to include these low-risk patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?